
HBV genotype A2 subtype adw (isolate Japan/Nishioka/1983) Capsid protein 19-27, LPSDFFPSV
Description
About HBV genotype A2 subtype adw (isolate Japan/Nishioka/1983) Capsid protein 19-27, LPSDFFPSV
The Hepatitis B Virus (HBV) genotype A2 subtype adw (isolate Japan/Nishioka/1983) Capsid protein Peptide (IEDB: 38701) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Capsid protein Peptide, H-LPSDFFPSV-OH (Uniprot: P03149 aa: 19-27) from JPT is produced under strict quality control and quality management.
HBV genotype A2 subtype adw (isolate Japan/Nishioka/1983) Capsid protein 19-27, LPSDFFPSV - Specifications
- Peptide sequence: H-LPSDFFPSV-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Hepatitis
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Peptide Synthesis Services!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for HBV genotype A2 subtype adw (isolate Japan/Nishioka/1983) Capsid protein 19-27, LPSDFFPSV
References:
Read References with JPT’s Antigen Peptides
HBV genotype A2 subtype adw (isolate Japan/Nishioka/1983) Capsid protein 19-27, LPSDFFPSV has been described in:
Degenerate immunogenicity of an HLA-A2-restricted hepatitis B virus nucleocapsid cytotoxic T-lymphocyte epitope that is also presented by HLA-B51., J Virol, 2001 (PMID: 11264388)
Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis., J Clin Invest, 1997 (PMID: 9239396)
Comprehensive Analysis of the Naturally Processed Peptide Repertoire: Differences between HLA-A and B in the Immunopeptidome., PLoS One, 2015 (PMID: 26375851)
Documentation
Documentation for HBV genotype A2 subtype adw (isolate Japan/Nishioka/1983) Capsid protein 19-27, LPSDFFPSV
Properties
Properties of HBV genotype A2 subtype adw (isolate Japan/Nishioka/1983) Capsid protein 19-27, LPSDFFPSV
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Hepatitis |
Layout: | Freeze-dried in glass vial |
Organism: | Hepatitis B Virus (HBV) |
Protein Name: | Capsid protein |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to HBV genotype A2 subtype adw (isolate Japan/Nishioka/1983) Capsid protein 19-27, LPSDFFPSV
Information | Values |
---|---|
Sequence: | H-LPSDFFPSV-OH |
Specifications: | 9mer peptide as TFA salt |